Search research articles
Contact Us
Filters
Showing results (1-10 of 3,921) with videos related to
Page
of 393
Sort By:
Pharmacoeconomics
|
January 9, 2026
The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective
Hangjian Wu, Cristina Fernandez-Garcia, Nicole O'Connor, et al.
Pharmacoeconomics
|
October 5, 2023
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective
Diarmuid Coughlan, Oluwatomi Arisa, Katie Thomson, et al.
Pharmacoeconomics
|
October 26, 2022
Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis
Corneliu Bolbocean, Sylvia van der Pal, Stef van Buuren, et al.
Pharmacoeconomics
|
December 3, 2024
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group Perspective
Sarah J Nevitt, David M Phillippo, Robert Hodgson, et al.
Pharmacoeconomics
|
October 18, 2022
In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives
Stefan A Lipman, Brigitte A B Essers, Aureliano P Finch, et al.
Pharmacoeconomics
|
October 13, 2022
Efficiency of the EmERGE Pathway of Care in Five European HIV Centres
Eduard J Beck, Sundhiya Mandalia, Platon Yfantopoulos, et al.
Pharmacoeconomics
|
December 21, 2014
Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective
Rizwan Hamid, Clara Loveman, Jim Millen, et al.
Pharmacoeconomics
|
October 16, 2014
Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies
Marieke Krol, Jocé Papenburg, Job van Exel
Pharmacoeconomics
|
November 22, 2014
Objectivity and equity: clarity required. A response to Hill and Olson
Mike Paulden, James F O'Mahony, Anthony J Culyer, et al.
Pharmacoeconomics
|
November 1, 2015
Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada
William Herring, Isobel Pearson, Molly Purser, et al.
Page
of 393
Search research articles
Search
Showing results (1-10 of 3,921) with videos related to
Sort By:
Page
of 393
Pharmacoeconomics
|
January 9, 2026
The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective
Hangjian Wu, Cristina Fernandez-Garcia, Nicole O'Connor, et al.
Pharmacoeconomics
|
October 5, 2023
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective
Diarmuid Coughlan, Oluwatomi Arisa, Katie Thomson, et al.
Pharmacoeconomics
|
October 26, 2022
Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis
Corneliu Bolbocean, Sylvia van der Pal, Stef van Buuren, et al.
Pharmacoeconomics
|
December 3, 2024
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group Perspective
Sarah J Nevitt, David M Phillippo, Robert Hodgson, et al.
Pharmacoeconomics
|
October 18, 2022
In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives
Stefan A Lipman, Brigitte A B Essers, Aureliano P Finch, et al.
Pharmacoeconomics
|
October 13, 2022
Efficiency of the EmERGE Pathway of Care in Five European HIV Centres
Eduard J Beck, Sundhiya Mandalia, Platon Yfantopoulos, et al.
Pharmacoeconomics
|
December 21, 2014
Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective
Rizwan Hamid, Clara Loveman, Jim Millen, et al.
Pharmacoeconomics
|
October 16, 2014
Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies
Marieke Krol, Jocé Papenburg, Job van Exel
Pharmacoeconomics
|
November 22, 2014
Objectivity and equity: clarity required. A response to Hill and Olson
Mike Paulden, James F O'Mahony, Anthony J Culyer, et al.
Pharmacoeconomics
|
November 1, 2015
Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada
William Herring, Isobel Pearson, Molly Purser, et al.
Page
of 393